viagra cialis levitra
viagra cialis levitra
To aid in the public health and clinical efforts to combat the first chronic disease to be declared a global epidemic. Metabolon is developing a practical, fasting blood test that provides a quantitative, tractable measure of glucose metabolism for the patient and physician, as a predictive risk assessment tool for those at-risk for Type 2 diabetes. This diagnostic solution is named Quantose™.
According to the Centers for Disease Control and Prevention (CDC), 25.8 million children and adults in the U.S., or 8.3% of the population, have diabetes. While an estimated 18.8 million have been diagnosed with Type 2 diabetes, approximately 7 million are unaware they have the disease. Based on glycemic measures from 2005-2008, the CDC reported that 35% of the U.S. adult population had pre-diabetes, yielding an estimated 79 million U.S. adults at risk for developing Type 2 diabetes. With the total annual cost associated with diabetes treatment at $174 billion (2007) in the U.S. alone, preventing and managing diabetes and its complications represents global public health challenges and priorities for healthcare systems.
With costly diabetic complications including cardiovascular disease, retinopathy, neuropathy, and nephropathy, significant unmet medical needs exist in both detecting and risk-stratifying patients who are at high risk for progressing to Type 2 diabetes, as well as determining appropriate therapy and predicting long-term outcomes in the diabetes setting.
Using its metabolomics-driven , Metabolon has discovered a number of significant biochemical markers indicative of risk for Type 2 diabetes. These markers are currently being incorporated in the development of the Quantose™ series of diagnostic products. The first-generation Quantose™ product is a diagnostic test for better identifying high-risk, insulin-resistant patients and predicting their risk of progression to Type 2 diabetes, above and beyond traditional risk factors and glycemic tests. The validated test is currently being offered in Metabolon’s CLIA laboratory as Investigational Use Only. The Quantose™ product applications will be targeted at different stages of the Type 2 diabetes continuum, pre-diabetes and therapeutic monitoring, with the goal of increasing effectiveness of preventing the disease and its complications.
